Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis

Figure 1 Risk of bias in included trials. A: Adequate sequence generation; B: Allocation concealment; C: Blinding; D: Incomplete outcome data addressed; E: Free of selective reporting; F: Free of other bias. 1: No (high risk of bias); 2: Unclear; 3: Yes (low risk of bias).

Figure 2 Meta-analysis of the two groups. A: Hepatitis B virus DNA undetectability; B: Alanine aminotransferase normalization; C: Hepatitis B e antigen (HBeAg) loss; D: HBeAg seroconversion; E: Drug-resistance; F: Increased creatine kinase (CK). ETV: Entacavir; LDT: Telbivudine.

Figure 3 Funnel plots of the two groups in hepatitis B virus DNA undetectability. RR: Relative risk;